Clinical Trial Update: SBRT and Atezolizumab in the Management of Recurrent, Persistent, or Metastatic Cervical Cancer [Phase 2]

View source ↗

Summary

This update describes a Phase 2 trial evaluating SBRT combined with Atezolizumab for recurrent, persistent, or metastatic cervical cancer; the study is currentl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Cervical Cancer Metastatic
• Cervical Cancer Recurrent

Drugs mentioned

• Atezolizumab (Tecentriq) (atezolizumab)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Cervical Cancer, Cervical Cancer Recurrent | Phase 2 | Status: ACTIVE_NOT_RECRUITING